Home Sectors Healthcare Latest Valuation: Incyte Corporation (NASDAQ: INCY)

Latest Valuation: Incyte Corporation (NASDAQ: INCY)


Incyte Corporation is part of the biotechnology industry and healthcare sector. Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.

Previous Intraday Trading Performance:

The INCY stock showed a previous change of 1.30% with an open at 79.50 and a close of 80.87. It reached an intraday high of 80.91 and a low of 79.41.

Business Wire:  Incyte Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease


The stock has a market cap of $17.2b with 212.8m shares outstanding, of which the float is 210.2m shares. Trading volume reached 987,532 shares compared to its average volume of 1,723,466 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Incyte Corporation shares returned -0.89% and in the past 30 trading days it returned 29.72%. Over three months, it changed 27.72%. In one year it has changed -13.55% and within that year its 52-week high was 96.33 and its 52-week low was 57.00. INCY stock is 41.88% above its 52 Week Low.

Our calculations show a 200 day moving average of 68.34 and a 50 day moving average of 71.36. Currently INCY stock is trading 18.34% above its 200 day moving average.

Business Wire:  Incyte Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease


The last annual fiscal EPS for the company was reported at -1.57 that ended on 31st of December 2017. Based on 2 analyst estimates, the consensus EPS for the next quarter is 0.25. The TTM EPS is 0.17, which comes to a TTM PE of 475.71.

The following are the last four quarter reported earnings per share:
09-30-2018:  0.20
06-30-2018:  0.13
03-31-2018:  -0.18
12-31-2017:  0.02

Base on our calculations, the intrinsic value per share is 57.64, which means it may be overvalued by -40.30%

Indicators to Watch:

Based on the latest filings, there is 123.70% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.38

SeekingAlpha:  How To Save $1.5 Million Starting At 40

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is -6.16%, return on assets is -4.48%, profit margin is 2.99%, price-to-sales is 12.55 and price-to-book is 9.55.

Company Scores:

All scores are out of six:
 0  :Valuation Score
 0  :Past Performance Score
 6  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 2  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.